These results suggest that PARP-1 inhibitors may non-specifically inhibit the growth of mammary tumors.Scott H KaufmannPuhalla S: PARP inhibitors: what we know and what we have yet to know. Oncology (Williston Park) 2010, 24(1):62, 65-6....
Liu, J.F.; Matulonis, U.A. What is the place of PARP inhibitors in ovarian cancer treatment? Curr. Oncol. Rep. 2016, 18, 29. [CrossRef] [PubMed]Liu JF, Matulonis UA. 2016. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? Curr. Oncol. Rep. 18(5):29...
Synthetic lethal therapies for cancer: What's next after PARP inhibitors? Nat. Reviews. Clin. Oncol. 2018, 15, 564-576. [CrossRef]Ashworth A, Lord CJ: Synthetic lethal therapies for cancer: what's next after PARP inhibitors? Nat Rev Clin Oncol 2018,...
Ovarian cancerPARP inhibitorsDrug resistanceClinical trialsDrug targetsAlthough the use of PARP inhibitors is a huge step forward, it is apparent that patients, both with and without BRCA-mutant ovarian cancer, will eventually become resistant to PARP inhibitors. Therefore, novel combination therapies ...
a flow cytometry assay, such as Annexin V, with fluorescently conjugated cleaved caspase/substrate antibodies. If examining tissue, then perhaps choose TUNEL along with IHC-based caspase activation. Live cell observation, on the other hand, may call for evaluating the effects of caspase inhibitors....
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? Poly-ADP-ribose polymerase (PARP) inhibitors have Matulonis,Ursula,A.,... - 《Current Oncology Reports》 被引量: 8发表: 2016年 PARP inhibition in ovarian cancer: what is still missing? 1Ludwig Institute for Cancer Research, ...
et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 347, 273–277 (2015). CAS PubMed PubMed Central Google Scholar O'Sullivan, R. J. et al. Rapid induction of alternative lengthening of telomeres by depletion of the histone chaperone ASF1...
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer EBioMedicine, Volume 60, 2020, Article 102988 Goldie Y.L. Lui,…, Carla Grandori View PDF Comprehensive platelet phenotyping supports the role of platelets in the pathogenesis of acute ven...
The main source of these types of lesions are chemotherapeutic agents, such as inhibitors of topoisomerase II (Top2), which covalently link it to the DNA ends (Nitiss, 2009). To repair these breaks, the adduct needs to be removed to allow the DNA repair machinery to access the break. ...
they undergo abbreviated approval processes, they are both versions of brand name drugs, and they share the same active ingredients as the brand name drugs. Both drugs are also useful because they “help to complete the cost of clinical trials and shorten the time that we can get these...